Raymond James Financial Services Advisors Inc. Purchases 884 Shares of Insulet Co. (NASDAQ:PODD)

Raymond James Financial Services Advisors Inc. increased its stake in shares of Insulet Co. (NASDAQ:PODD) by 26.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 4,284 shares of the medical instruments supplier’s stock after purchasing an additional 884 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Insulet were worth $930,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of PODD. Parkside Financial Bank & Trust increased its position in shares of Insulet by 251.0% during the 3rd quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 123 shares during the last quarter. Allworth Financial LP increased its position in shares of Insulet by 104.5% during the 3rd quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 92 shares during the last quarter. Wolff Wiese Magana LLC increased its position in shares of Insulet by 2,680.0% during the 4th quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 134 shares during the last quarter. BluePath Capital Management LLC bought a new position in shares of Insulet during the 3rd quarter valued at approximately $31,000. Finally, First Manhattan Co. bought a new position in shares of Insulet during the 4th quarter valued at approximately $35,000.

Insider Buying and Selling

In related news, Director Shacey Petrovic sold 11,609 shares of the company’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the completion of the sale, the director now directly owns 2,567 shares in the company, valued at approximately $418,215.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.80% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on PODD shares. Barclays cut their target price on Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a research report on Monday, February 26th. Stifel Nicolaus boosted their price objective on Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a report on Monday, February 5th. Piper Sandler dropped their price objective on Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a report on Friday, February 23rd. JPMorgan Chase & Co. boosted their price objective on Insulet from $190.00 to $225.00 and gave the company an “overweight” rating in a report on Friday, February 23rd. Finally, Robert W. Baird upgraded Insulet from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $180.00 to $238.00 in a report on Thursday, December 21st. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Insulet has a consensus rating of “Moderate Buy” and a consensus target price of $250.33.

Insulet Price Performance

Shares of PODD stock opened at $173.94 on Tuesday. Insulet Co. has a twelve month low of $125.82 and a twelve month high of $335.91. The stock has a market capitalization of $12.18 billion, a price-to-earnings ratio of 59.77, a P/E/G ratio of 3.15 and a beta of 0.98. The stock has a fifty day simple moving average of $176.32 and a two-hundred day simple moving average of $178.90. The company has a current ratio of 3.51, a quick ratio of 2.62 and a debt-to-equity ratio of 1.86.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.73. The firm had revenue of $509.80 million during the quarter, compared to analysts’ expectations of $461.26 million. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The firm’s quarterly revenue was up 37.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.55 EPS. On average, analysts predict that Insulet Co. will post 3.08 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.